Lancet Neurology [2011] 10 (5) : 415-423 (O.Rascol, C.J. Fitzer-Attas, R.Hauser, J.JankovicJ, A.Lang, J.W.Langston, E. Melamed, W.Poewe, F.Stocchi, E.Tolosa, E.Eyal, Y.M.Weiss, C. W.Olanow) Complete abstract

The ADAGIO study investigated whether Rasagiline has disease-modifying effects in Parkinson's Disease. Rasagiline is a MAO-B inhibitor, that is also known by the brand name Azilect. For more information go to Azilect. Rasagiline 1 mg per day, but not 2 mg per day, was previously shown to have some effect. The present study reported the secondary analysis. The need for additional Parkinson's Disease drugs after using Rasagiline occurred in only 9% of people with both 1mg or 2mg Rasagiline, but 18% when the initiation of Rasagiline was delayed for 36 weeks.  After 36 weeks both 1mg and 2mg improved Parkinson's Disease symptoms, but only moderately, just as occurred with previous studies. Both doses of Rasagiline also moderately improved fatigue and ADL (activities of daily living), with 2mg being slightly better than 1mg. Mental activity was improved slightly using 1mg Rasagiline. Those people that delayed the use of Rasagiline started to deteriorate in their symptoms prior to starting Rasagiline, especially in those with more severe symptoms.  For more current news go to Parkinson's Disease News.

Parkinson's Disease News details all significant new research, news reports, new books, and new resources concerning Parkinson's Disease and those medical disorders that often coincide with Parkinson's Disease. It is compiled from an analysis of  all newly published research, news reports, new clinical trials, all newly published books, and new web sites. A summary and analysis of the new research are provided,  as well as links to the complete abstracts and news reports